Found 81 articles for: "onychomycosis"
Number of Affected Nails Is the Primary Determinant of Efinaconazole 10% Solution Usage for Onychomycosis
February 2024 | Volume 23 | Issue 2 | Editorials | 110 | Copyright © February 2024
Good adherence to treatment is necessary for the successful treatment of onychomycosis and requires that an appropriate amount of medication be prescribed. Most prescriptions for efinaconazole 10...
Read MoreObjective Facial Assessment With Artificial Intelligence: Introducing the Facial Aesthetic Index and Facial Youthfulness Index
January 2024 | Volume 23 | Issue 1 | Editorials | e52 | Copyright © January 2024
CO2 Laser Matricectomy for the Treatment of Pincer Nail Deformity: A Retrospective Cohort Study
November 2023 | Volume 22 | Issue 11 | Original Article | 1099 | Copyright © November 2023
Background: Pincer nail deformity (PND) is a common toenail disorder characterized by transverse over-curvature of the nail plate. It can cause severe pain, chronic inflammation,...
Read MoreEpidemiology of Chronic Dermatologic Conditions in Skin of Color
November 2023 | Volume 22 | Issue 11 | Features | e21 | Copyright © November 2023
Across the board, common dermatologic conditions disproportionately affect patients of color. While the causes of these disparities have been tied to the environment, societal structure, access t...
Read MoreOnychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
October 2023 | Volume 22 | Issue 10 | Original Article | 1040 | Copyright © October 2023
Background: Onychomycosis represents the highest proportion of nail disorders seen in clinical practice. Onychomycosis management may differ amongst specialties, with impact on patien...
Read MoreComparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Recently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medica...
Read MoreFULL SUPPLEMENT: Optimizing Transungal Efficacy at the Site of the Infection With Efinaconazole
September 2023 | Volume 22 | Issue 9 | Department | SF378719s5 | Copyright © September 2023
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US w...
Read MoreIndividual Article: Updated Review of Topical Pharmaceuticals and Complementary and Alternative Medications for the Treatment of Onychomycosis in Both General and Special Populations in the United States
September 2023 | Volume 22 | Issue 9 | Supplement Individual Articles | SF378719 | Copyright © September 2023
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US w...
Read MoreBrodalumab: 4-Year US Pharmacovigilance Report
April 2023 | Volume 22 | Issue 4 | Features | 419 | Copyright © April 2023
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. B...
Read MoreArtificial Intelligence in Hair and Nail Disorders
October 2022 | Volume 21 | Issue 10 | Original Article | 1049 | Copyright © October 2022
Artificial intelligence (AI), a field of computer science, aims at simulating human intelligence with computers. Though AI has surpassed dermatologists in skin cancer detection, it still lags behind v...
Read MoreSevere Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
August 2022 | Volume 21 | Issue 8 | Case Reports | 897 | Copyright © August 2022
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of ...
Read MoreFuture Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline
May 2022 | Volume 21 | Issue 5 | Original Article | 496 | Copyright © May 2022
Over the last decade, major advances in antifungal drug development have occurred. Novel drugs in the pipeline include ME1111, MAT2203, rezafungin, ibrexafungerp, olorofim, fosmanogepix, MGCD290, VT-1...
Read MoreCurrent Issues in Global Onychomycosis Management
April 2022 | Volume 21 | Issue 4 | Original Article | 371 | Copyright © April 2022
Introduction: Onychomycoses occur worldwide and are complex infections to treat. Diagnosis with standard culture methods has been problematic. Treatment historically used oral monothe...
Read MoreTherapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US
October 2021 | Volume 20 | Issue 10 | Original Article | 1076 | Copyright © October 2021
Background: Onychomycosis affects around 14% of individuals in North America and Europe and is undertreated. Treatment is challenging as toenail growth can take 12–18 months, th...
Read MoreSafety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients
September 2020 | Volume 19 | Issue 9 | Original Article | 867 | Copyright © September 2020
Background: Pediatric onychomycosis management is challenging as there are limited treatment options. The objective of this study was to evaluate efinaconazole 10% topical solution in...
Read MoreUse of In-Office Preparations by Dermatologists for the Diagnosis of Cutaneous Fungal Infections
August 2019 | Volume 18 | Issue 8 | Original Article | 798 | Copyright © August 2019
Cutaneous fungal infections account for millions of office visits per year, yet their varied presentations often lead to misdiagnosis. If dermatology clinics are Clinical Laboratory Improvement Amendm...
Read MoreEvaluation of Onychomycosis Information on the Internet
May 2019 | Volume 18 | Issue 5 | Editorials | 484 | Copyright © May 2019
Onychomycosis is a common and significant nail condition causing both physical and social impairment. Since patients often search for health information online, the accuracy of this information has be...
Read MoreLaser Treatment of Skin of Color for Medical and Aesthetic Uses With a New 650-Microsecond Nd:YAG 1064nm Laser
April 2019 | Volume 18 | Issue 4 | Supplement Individual Articles | 135 | Copyright © April 2019
Individuals with skin of color are a rapidly growing portion of the cosmetic procedures market. There are unique challenges to treating skin conditions in skin of color patients. This article and roun...
Read MoreTavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study
February 2019 | Volume 18 | Issue 2 | Original Article | 190 | Copyright © February 2019
BACKGROUND: This study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of tavaborole in pediatric patients. Study Design: In this open-label, single-arm study, ...
Read MoreA Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis
August 2018 | Volume 17 | Issue 8 | Original Article | 888 | Copyright © August 2018
Background: Tinea pedis, or athlete’s foot, is a superficial, skin infection caused by dermatophytes. It is usually topically treated. Nitric oxide is endogenously produced in humans and has a varie...
Read MoreMedia and other results for: "onychomycosis"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
